MedTrace Logo

Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment

NCT02111434 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2014-04-14

No results posted yet for this study

Summary

The study is designed to answer the following questions:

1. What is the levels of visceral adiposity index and Triglycerides/HDL cholesterol ratio in hypogonadism?
2. What is the effect of testosterone replacement on the visceral adiposity index and Triglycerides/HDL cholesterol ratio?

Conditions

  • Hypogonadism

Interventions

DRUG

Testosterone

Testosterone 250 mg injection per 3-4 weeks for 6 months

Sponsors & Collaborators

  • Gulhane School of Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
26 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02111434 on ClinicalTrials.gov